Athenex

$12.20
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.28 (-2.30%) Today
+$0.33 (+2.78%) As of 1:37 PM UTC after-hours

Why Robinhood?

You can buy or sell Athenex and other stocks, options, and ETFs commission-free!

About ATNX

Athenex, Inc. Common Stock, also called Athenex, is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients (APIs) for clinical and commercial efforts. The Commercial Platform segment involves in the sales and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY. The listed name for ATNX is Athenex, Inc. Common Stock.

CEO
Yiu Nam Lau
Employees
574
Headquarters
Buffalo, New York
Founded
2003
Market Cap
1.09B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.57M
High Today
$12.45
Low Today
$11.65
Open Price
$12.32
Volume
1.78M
52 Week High
$15.24
52 Week Low
$5.63

ATNX Earnings

-$0.45
-$0.30
-$0.15
-$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.44 per share
Actual
Available Mar 1, Pre-Market

You May Also Like

NPO
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure